Event in Progress:
View the latest research on other companies in the sector.
The 2022 annual results do not bring any surprises. The major point of the communication is the extension of financial visibility to Q2 2024.TP adjusted to EUR 16.2, Buy rating reiterated.
Abivax Abivax SA
Abivax released final results from the Phase 2b study in UC, further confirming the good performance of obefazimod.Overall, the company has made a series of positive announcements that should revive investor interest. We upgrade our recommendation to Buy with an adjusted TP of EUR 13.5.
Abivax has raised a record EUR 130m in equity financing.The transaction, which was done without a discount on the share price and involved around fifteen specialized European and American investors, shows a strong appetite for the stock.Financial visibility extended to Q2 2024 (compared to Q1 2023 previously).
Share: